Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Angiodynamics (ANGO) EBIT Margin (2016 - 2026)

Angiodynamics' EBIT Margin history spans 17 years, with the latest figure at 16.51% for Q1 2026.

  • For Q1 2026, EBIT Margin fell 266.0% year-over-year to 16.51%; the TTM value through Feb 2026 reached 11.32%, up 584.0%, while the annual FY2025 figure was 13.66%, 4966.0% up from the prior year.
  • EBIT Margin reached 16.51% in Q1 2026 per ANGO's latest filing, down from 7.71% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 44.52% in Q3 2023 to a low of 265.88% in Q1 2024.
  • Average EBIT Margin over 5 years is 25.09%, with a median of 14.07% recorded in 2025.
  • Peak YoY movement for EBIT Margin: plummeted -25482bps in 2024, then surged 25203bps in 2025.
  • A 5-year view of EBIT Margin shows it stood at 9.5% in 2022, then tumbled by -75bps to 16.59% in 2023, then grew by 8bps to 15.23% in 2024, then skyrocketed by 49bps to 7.71% in 2025, then plummeted by -114bps to 16.51% in 2026.
  • Per Business Quant, the three most recent readings for ANGO's EBIT Margin are 16.51% (Q1 2026), 7.71% (Q4 2025), and 14.07% (Q3 2025).